

## **West Virginia Medicaid Drug Utilization Review Board Minutes September 28, 2022**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

### **Members:**

Christopher Terpening, PharmD, PhD, Chair  
David Gloss, MD, Vice Chair  
Chris Booth, PharmD  
Scott Brown, RPh  
Kate Forman, PharmD  
Phillip Galapon, MD  
Lester Labus, MD  
C.K. Babcock, PharmD  
Michael Ballow, PharmD  
Mary Nemeth-Pyles, MSN, RN, CS

### **Members Absent:**

Michael Lonsinger, PharmD  
K.C. Lovin, PA-C  
Ernest Miller, DO

### **DHHR/BMS Staff present:**

Brian Thompson, MS, PharmD, Director of Pharmacy Services  
Priya Shah, PharmD, Drug Utilization Review Coordinator  
Lori Moles, RPh, Staff Pharmacist  
Doug Sorvig, Data Analyst  
Gail Goodnight, RPh, Rebate Manager

### **DHHR/BMS Staff absent:**

Bill Hopkins, Pharmacy Operations Manager

### **Contract Staff:**

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)  
Kim Broedel-Zaugg, RPh, PhD, Marshall University  
Rob Stanton, PharmD, MBA, Marshall University  
Jon Willis, Marshall University  
Eric Sears, RPh, Gainwell  
Joe Bergondo, PharmD, Change Healthcare  
Jeffrey Barkin, MD, Change Healthcare

#### **I. INTRODUCTIONS**

- a. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:03 pm EDT. The DUR Board and others introduced themselves.

#### **II. APPROVAL OF MINUTES FROM May 25, 2022 DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

**III. OLD BUSINESS**

**IV. NEW BUSINESS**

**a. Speakers**

- i. None

**b. Updates from August 24, 2022 P & T Committee Meeting.** Attachment A.

- i. Joseph Bergondo presented the updates from the August 24<sup>th</sup>, 2022 P & T meeting

**c. Proposed Prior Authorization Criteria:**

- i. **Celecoxib:** approved as presented
- ii. **Seglentis ;** approved as presented
- iii. **Cibinqo, Rinvoq-atopic dermatitis:** approved as presented
- iv. **Fleqsuvy/baclofen solution:** approved as presented
- v. **Voxzogo:** approved as presented
- vi. **Ibsrela:** approved as presented
- vii. **Norliqva:** approved as presented
- viii. **Vaginal ring contraceptives:** approved as presented
- ix. **Testosterone (injectable):** approved as amended, will expand to other agents in category and allow for exceptions in gender transitions therapy.

**V. REPORTS –2<sup>nd</sup> Quarter 2022**

- a. **Gainwell Technologies Quarterly Report:** Mr. Sears presented an overview of the 2022 Second Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the Second Quarter of 2022. Attachment C.
- c. **Marshall University:** Dr. Stanton presented a review of the RDUR Second of Quarter 2022 activities. Attachment D.

**VI. OTHER BUSINESS**

**VII. NEXT MEETING AND ADJOURNMENT**

- VIII. a. The meeting concluded at 5:35 pm EDT.
- b. The next meeting will be November 16, 2022 from 4-6pm on virtual platform.